Contact Us
News
Company
About Us
Leadership
Board of Directors
Partner With Us
Corporate Responsibility
Contact Us
Our Focus
Overview
Hyperhidrosis
Atopic Dermatitis
Helpful Resources
Grants & Sponsorships
Our Medicines
QBREXZA™ (glycopyrronium) cloth
R&D
Pipeline
Lebrikizumab
Clinical Trials
Early Research Program
Medical Information
Careers
Culture & Values
Job Openings
Investors & Media
Investor Overview
Stock Information
News Releases
Media Resources
Events & Presentations
Corporate Governance
Financial Filings
Investor FAQs
Information Request
MENU
MENU
mobile
Company
About Us
Leadership
Board of Directors
Partner With Us
Corporate Responsibility
Contact Us
Our Focus
Overview
Hyperhidrosis
Atopic Dermatitis
Helpful Resources
Grants & Sponsorships
Our Medicines
QBREXZA™ (glycopyrronium) cloth
R&D
Pipeline
Lebrikizumab
Clinical Trials
Early Research Program
Medical Information
Careers
Culture & Values
Job Openings
Investors & Media
Investor Overview
Stock Information
Stock Quote & Chart
Historical Price
Investment Calculator
Analyst Coverage
News Releases
Media Resources
Events & Presentations
Corporate Governance
Leadership Team
Board of Directors
Committee Composition
Documents & Charters
Financial Filings
SEC Filings
Investor FAQs
Information Request
Contact Us
News
FOLLOW US
Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A Phase IIa, multicenter, randomized, vehicle-controlled study.
Investors Overview
Stock Information
Stock Quote & Chart
Historical Price Lookup
Investment Calculator
Analyst Coverage
News Releases
Media Resources
Events & Presentations
Corporate Governance
Leadership
Board of Directors
Committee Composition
Documents & Charters
Financial Filings
SEC Filings
Annual Reports
Investor FAQs
You Are Now Leaving Dermira.com
RETURN
CONTINUE